Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Marpai, Inc. filings document material events, capital-structure matters and operating disclosures for a healthcare technology company whose Class A common stock trades on the OTCQX Market under MRAI. Recent Form 8-K reports cover results of operations, material definitive agreements and governance matters.
The filing record includes disclosures on promissory-note financing for working capital, amendments to note terms, officer appointments, and charter changes authorizing blank-check preferred stock. Marpai filings also identify its registered Class A common stock, emerging growth company status in certain reports, and formal risk and compliance references tied to its public-company reporting obligations.
Marpai, Inc. amended its charter to authorize 2,000,000 shares of blank-check preferred stock. This gives the board the ability to create one or more series of preferred shares with voting powers, preferences, and other rights set solely by the board.
The board approved the amendment on June 24, 2025; a majority of stockholders approved it at the annual meeting on August 27, 2025; and the amendment was filed in Delaware on October 17, 2025.
Marpai, Inc. (MRAI) — insider share sales reported. A reporting person filed a Form 4 showing open‑market sales of Common Shares on multiple dates: 10,000 shares at $1.43 on 08/13/2025; 20,000 at $1.40 on 08/15/2025; 20,000 at $1.40 on 08/18/2025; 20,000 at $1.40 on 08/19/2025; 10,000 at $1.42 on 08/20/2025; and 14,000 at $1.63 on 10/06/2025. Following the reported transactions, the filing lists 1,770,707 shares beneficially owned. The reporting person is indicated as a Director. Footnotes state the shares are held by IFCM MicroCap Fund LP, with Intelligent Fanatics Capital Management LLC as general partner; Mr. Cassel may be deemed a beneficial owner through shared voting and investment power and disclaims beneficial ownership except to the extent of his interests.
Marpai, Inc. (MRAI) filed an Form 8-K reporting a material event that attaches a Form of Securities Purchase Agreement as Exhibit 10.1 and an inline XBRL cover page file as Exhibit 104. The filing lists corporate communications categories related to securities and solicitation rules and identifies the security as Class A Common Stock traded on OTCQX. The form is signed by Damien Lamendola, Chief Executive Officer, with a signature date of October 6, 2025. The filing text supplied here does not include the agreement terms, financing amounts, counterparties, or other transaction economics, so material financial details are not available in this excerpt.
Marpai, Inc. (MRAI) director and CEO Damien Lamendola reported transactions dated 09/30/2025. He acquired 147,058 shares of Class A common stock at $1.36 per share and disposed of 800,000 shares on the same date. After these reported transactions, his beneficial ownership is stated as 6,419,893 shares, held indirectly through entities he controls as described in the footnotes. The filing shows two indirect holdings: shares held by HillCour Investment Fund, LLC (managed by Mr. Lamendola) and shares held by WellEnterprises USA, LLC, which is controlled through HillCour affiliates. The form is signed by Mr. Lamendola.
Marpai, Inc. director, Chief Executive Officer, and over-10% holder Damien Lamendola reported an indirect open‑market purchase of 896,903 shares of Class A common stock at an average price of $1.0592 per share. The shares are held by entities including HillCour Investment Fund, LLC and WellEnterprises USA, LLC, over which he holds voting and dispositive power. Following these transactions, his reported holdings include 6,272,835 indirect shares, 800,000 direct shares, and an additional 931,674 indirect shares of Class A common stock.
Marpai, Inc. (MRAI) director Shiv Sagiv amended a Form 4 to correct reported beneficial ownership after the vesting of restricted stock units (RSUs). The amendment shows 75,000 Class A common shares were acquired on 08/19/2025 through RSU vesting at no cash price, and the Reporting Person now beneficially owns 147,000 shares. The filing states the RSUs vested in three equal tranches of 25,000 shares at three, six and nine months after the grant date, and the amendment corrects an earlier filing that misstated the post-transaction ownership total.
Marpai, Inc. director Eitan Yaron received 75,000 restricted stock units (RSUs) that vested on a nine-month schedule and now beneficially owns 864,073 shares following the reported transactions. The RSUs vested in three tranches of 25,000 shares at three, six and nine months after grant, and the filing amends a prior Form 4 to correct the previously misstated post-transaction ownership total.
Marpai, Inc. reported that on September 10, 2025, it entered into a Securities Purchase Agreement with three investors for a private sale of its Class A common stock. The company agreed to issue and sell 1,038,519 shares of common stock at $1.0592 per share.
The investor group includes HillCour Investment Fund, LLC, an entity controlled by Chief Executive Officer Damien Lamendola, which purchased 896,903 shares. The transaction was structured as a private placement relying on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The shares have not been registered and may only be resold in the United States under a registration statement or a valid exemption.
Marpai, Inc. (MRAI) director Eitan Yaron acquired 75,000 restricted stock units (RSUs) on 08/19/2025 under a grant that vests in three equal tranches over nine months. The filing reports these RSUs were recorded at $0 price and, after the grant, Mr. Yaron beneficially owns 1,542,527 shares. The Form 4 indicates the reporting person is a director and the transaction was a non-derivative acquisition of Class A common stock RSUs.
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock. The filing indicates the RSUs were granted under a plan with a nine-month vesting schedule: 25,000 RSUs vested at three months, 25,000 at six months, and 25,000 at nine months.
The Form 4 was signed on 09/15/2025 and notes the transaction was made pursuant to a plan intended to meet the Rule 10b5-1 affirmative defense. Sagiv is identified as a director. No options or derivative transactions are reported in this filing.